{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:33:49Z","timestamp":1787070829352,"version":"build-2736575974"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Malignant pleural mesothelioma (MPM) is a pleural tumor with high mortality rate and short-term survival expectancy after diagnosis. Assessment of the response to chemotherapy, which is the first choice in treatment of MPM, is important for the transition to alternative chemotherapy protocols and immunotherapy. There is no clarity in the response to chemotherapy treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>Our study aims to compare the assessment of chemotherapy response using the Modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria and volumetric measurements and to correlate with median survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>Thirty-two patients (16 females and 16 males) were included in the study, and their ages ranged from 28 to 78 years. Chemotherapy response was determined by both mRECIST and volumetric approach. Tumor volume was measured by linear interpolation and semi-automatic segmentation. Log-rank multiple cutoff analysis was used to determine appropriate cutoff values of volumetric response criteria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      According to both mRECIST and volumetric approach, median survival times in partial response, stable disease, and progressive disease groups were 24, 15, and 9 months, respectively. The survival times of the three groups were different (logrank: 17.76;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001) by mRECIST. The survival of the progressive disease group was shorter than that of the other groups (logrank: 18.91;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001) by volumetric approach.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>In the assessment of chemotherapy response, even though classifications obtained according to the mRECIST criteria and volumetric measurements are statistically compatible, we think that the measurement of the volumetric values will increase the standardization. In our study, threshold values for volumetric measurements were determined; however, these values should be supported by large-scale multicenter studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_217_19","type":"journal-article","created":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T08:45:05Z","timestamp":1597826705000},"page":"69-74","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["The role of volumetric method in the assessment of chemotherapy response and predicting survival in malignant pleural mesothelioma"],"prefix":"10.4103","volume":"17","author":[{"given":"Furkan Erturk","family":"Urfali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selma","family":"Metintas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atila","family":"Gurgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AK","family":"Guntulu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ragip","family":"Ozkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muzaffer","family":"Metintas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-12-20241021","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/sj.bjc.6690105","article-title":"The European mesothelioma epidemic","volume":"79","author":"Peto","year":"1999","journal-title":"Br J Cancer"},{"key":"R2-12-20241021","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1200\/JCO.2017.76.6394","article-title":"Treatment of malignant pleural mesothelioma: American society of clinical oncology clinical practice guideline","volume":"36","author":"Kindler","year":"2018","journal-title":"J Clin Oncol"},{"key":"R3-12-20241021","doi-asserted-by":"crossref","first-page":"6881","DOI":"10.1200\/JCO.20005.14.589","article-title":"Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: An intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer \u0130nstitute of Canada","volume":"23","author":"van Meerbeeck","year":"2005","journal-title":"J Clin Oncol"},{"key":"R4-12-20241021","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"key":"R5-12-20241021","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.lungcan.2008.04.001","article-title":"The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma","volume":"63","author":"Stebbing","year":"2009","journal-title":"Lung Cancer"},{"key":"R6-12-20241021","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.lungcan.2014.03.006","article-title":"Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma","volume":"84","author":"Zauderer","year":"2014","journal-title":"Lung Cancer"},{"key":"R7-12-20241021","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S1470-2045(13)70381-4","article-title":"Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: An open-label, single-arm, phase 2 trial","volume":"14","author":"Calabr\u00f2","year":"2013","journal-title":"Lancet Oncol"},{"key":"R8-12-20241021","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.crad.2005.05.015","article-title":"Use of imaging in the management of malignant pleural mesothelioma","volume":"60","author":"Benamore","year":"2005","journal-title":"Clin Radiol"},{"key":"R9-12-20241021","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.2214\/ajr.172.4.10587144","article-title":"Staging of malignant pleural mesothelioma: Comparison of CT and MR imaging","volume":"172","author":"Heelan","year":"1999","journal-title":"AJR Am J Roentgenol"},{"key":"R10-12-20241021","doi-asserted-by":"crossref","first-page":"961","DOI":"10.2214\/ajr.159.5.1414807","article-title":"Malignant pleural mesothelioma: Value of CT and MR imaging in predicting resectability","volume":"159","author":"Patz","year":"1992","journal-title":"AJR Am J Roentgenol"},{"key":"R11-12-20241021","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.lungcan.2007.09.027","article-title":"Current state and future directions of pleural mesothelioma imaging","volume":"59","author":"Armato","year":"2008","journal-title":"Lung Cancer"},{"key":"R12-12-20241021","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","article-title":"Reporting results of cancer treatment","volume":"47","author":"Miller","year":"1981","journal-title":"Cancer"},{"key":"R13-12-20241021","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer \u0130nstitute of the United States, National Cancer \u0130nstitute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"R14-12-20241021","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.lungcan.2003.07.005","article-title":"Inadequacy of the new response evaluation criteria in solid tumors (RECIST) in patients with malignant pleural mesothelioma: Report of four cases","volume":"43","author":"Monetti","year":"2004","journal-title":"Lung Cancer"},{"key":"R15-12-20241021","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ctrv.2007.07.012","article-title":"Assessment of tumor response in malignant pleural mesothelioma","volume":"33","author":"Ceresoli","year":"2007","journal-title":"Cancer Treat Rev"},{"key":"R16-12-20241021","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0169-5002(03)00292-7","article-title":"Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesothelioma","volume":"43","author":"van Klaveren","year":"2004","journal-title":"Lung Cancer"},{"key":"R17-12-20241021","doi-asserted-by":"crossref","first-page":"348","DOI":"10.4161\/cbt.1.4.4","article-title":"The role of environmental carcinogens, viruses and genetic predisposition in the pathogenesis of mesothelioma","volume":"1","author":"Powers","year":"2002","journal-title":"Cancer Biol Ther"},{"key":"R18-12-20241021","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0954-6111(99)90318-9","article-title":"Environmental asbestos exposure and malignant pleural mesothelioma","volume":"93","author":"Metintas","year":"1999","journal-title":"Respir Med"},{"key":"R19-12-20241021","doi-asserted-by":"crossref","first-page":"ii","DOI":"10.3390\/ijerph14111293","article-title":"Turkey national mesothelioma surveillance and environmental asbestos exposure control program","volume":"14","author":"Metinta\u015f","year":"2017","journal-title":"Int J Environ Res Public Health"},{"key":"R20-12-20241021","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1378\/chest.108.4.1122","article-title":"A proposed new international TNM staging system for malignant pleural mesothelioma. From the international mesothelioma interest group","volume":"108","author":"Rusch","year":"1995","journal-title":"Chest"},{"key":"R21-12-20241021","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1053\/rmed.2001.1178","article-title":"Prognostic factors in diffuse malignant pleural mesothelioma: Effects of pretreatment clinical and laboratory characteristics","volume":"95","author":"Metintas","year":"2001","journal-title":"Respir Med"},{"key":"R22-12-20241021","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0022-5223(99)70469-1","article-title":"Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: Results in 183 patients","volume":"117","author":"Sugarbaker","year":"1999","journal-title":"J Thorac Cardiovasc Surg"},{"key":"R23-12-20241021","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S0022-5223(98)70274-0","article-title":"Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma","volume":"115","author":"Pass","year":"1998","journal-title":"J Thorac Cardiovasc Surg"},{"key":"R24-12-20241021","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1097\/JTO.0b013e3181dd0ef1","article-title":"Assessment of therapy responses and prediction of survival in malignant pleural mesothelioma through computer-aided volumetric measurement on computed tomography scans","volume":"5","author":"Liu","year":"2010","journal-title":"J Thorac Oncol"},{"key":"R25-12-20241021","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.athoracsur.2016.06.069","article-title":"A multicenter study of volumetric computed tomography for staging malignant pleural mesothelioma","volume":"102","author":"Rusch","year":"2016","journal-title":"Ann Thorac Surg"},{"key":"R26-12-20241021","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1118\/1.3525836","article-title":"Computerized segmentation and measurement of malignant pleural mesothelioma","volume":"38","author":"Sensakovic","year":"2011","journal-title":"Med Phys"},{"key":"R27-12-20241021","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1183\/09031936.00146110","article-title":"Volumetry: An alternative to assess therapy response for malignant pleural mesothelioma?","volume":"38","author":"Frauenfelder","year":"2011","journal-title":"Eur Respir J"},{"key":"R28-12-20241021","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1097\/JTO.0b013e318269fe21","article-title":"Optimization of response classification criteria for patients with malignant pleural mesothelioma","volume":"7","author":"Labby","year":"2012","journal-title":"J Thorac Oncol"},{"key":"R29-12-20241021","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ejrad.2009.02.002","article-title":"Three-dimensional evaluation of chemotherapy response in malignant pleural mesothelioma","volume":"74","author":"Ak","year":"2010","journal-title":"Eur J Radiol"},{"key":"R30-12-20241021","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1097\/JTO.0000000000000211","article-title":"Observer variability in mesothelioma tumor thickness measurements: Defining minimally measurable lesions","volume":"9","author":"Armato","year":"2014","journal-title":"J Thorac Oncol"},{"key":"R31-12-20241021","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1097\/JTO.0b013e3181ba2033","article-title":"Prognostic factors according to the treatment schedule in malignant pleural mesothelioma","volume":"4","author":"Ak","year":"2009","journal-title":"J Thorac Oncol"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_217_19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:37:16Z","timestamp":1787067436000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_217_19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_217_19","relation":{},"ISSN":["0973-1482"],"issn-type":[{"value":"0973-1482","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]}}}